Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 290-649-8 | CAS number: 90194-39-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Acute toxicity of the test item is addressed by read-across approach. Based on experimental data available for all source substances, lowest LD50 of 1080 mg LAS Na/kg bw/ was obtained in rats via the oral route. Via the dermal route no adverse effects were observed at doses up to 2000 and 13000 mg/kg bw tested with LAS Na and DEA, respectively.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 080 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
No experimental data on acute toxicity is available for the test item. However, experimental data for three source substances is available and a read-across approach is applied. Please refer to read-across justification document attached in IUCLID Section 13. Furthermore, only key studies are taken into account here. For further supporting information please refer to respective REACH registration dossier of each source substance.
Oral
CAS 121617 -08 -1
In an acute oral toxicity study 4 groups of young female and male Bor: WISW rats were given a single oral dose of Marlopon AT 50 (50% LAS TEA, 1% neutral oil, 1% triethanolamin, 3.5% treithanolaminesulfate, water) at doses of 3980, 5010, 6310, 10000 mg /kg bw mg/kg bw (dry material concentrations (CAS No 68411 -31 -4): 2211,2783, 3506, 5556 mg/kg bw) and observed for 14 days.
Oral LD50 Combined = 2925 mg dry material/kg bw
The dry material CAS 68411 -31-4 is of low toxicity based on the LD50in males and females. No classification and labelling for acute oral toxicity are required.
Treatment with the test product resulted in the following clinical signs that were observed approximately half to two hours after administration of the test material: sedation, ataxia, hypothermia, diarrhoea, cowering posture, tremor, horrent fur, dyspnoea, ventral position (temporarily) and diuresis. The symptoms dissappeared within 72 hours after treatment. Post mortem examinations revealed hyperaemia of mucous membranes of the GI tract in some animals; mucous membranes were partially pale. The GI tract contents were thin, foamy and slimy, partially showing yellow-orange or red-brownish discolouration. Some animals showed tympanites of stomach and intestine. Furthermore, the intestinal mucous membrane showed convulsion and hyperaemia in some animals. No effects were observed at the lowest dose tested.
CAS 68411 -30 -3:
This study examined the oral toxicity of the test substance in rats. Groups of 5 male and 5 female rats were exposed orally to 0, 1075, 1220, 1360, or 1710 mg/kg of test substance. The animals were then monitored for 14 days for mortality and clinical signs. All animals showed signs of toxicity. Mortality was seen at all dose levels, with 4 of 10 animals at the lowest dose level dying. All animals at the highest dose level died. The acute oral LD50, when adjusted for activity was 1080 mg/kg. According to EU GHS guidelines, the test substance is a Category IV toxicant.
CAS 111 -42 -2
Regarding the oral route of exposure, in a study (BASF AG, 1966), performed to a comparable protocol as OECD guideline 401, 5 rats per sex were dosed with 200 - 3200 mg/kg bw and observed up to 14 days. No deaths occurred up to 1000 mg/kg bw dosing group. The LD50 for males and females combined was 1600 mg/kg bw. Reported clinical signs were tumbling, staggering gait, twitches, convulsions, dyspnoea, abdominal lateral position and scrubby coat. Gross pathology revealed hydrothorax, local adhesions of the gut and signs of irritation on the gastro-intestinal tract.
Inhalation
In accordance with column 2 of REACH Annex VIII, in addition to the oral route, for substances other than gases, the information mentioned under 8.5.2 to 8.5.3 shall be provided for at least one other route. As acute dermal toxicity studies for read-across substances are available, no acute inhalation toxicity study is needed.
Dermal
CAS 68411 -30 -3
A GLP and OECD 402 compliant study was conducted with CAS 68411-30-3. The clipped skin on the backs of five male and five female rats were exposed to the test material under an occlusive dressing for 24 hours and observed for another 14 days. Results indicate slight erythema and slight oedema but no acute mortality. The dermal LD50 is > 2000 mg/kg.
CAS 111 -42 -2
Two secondary literature sources are available for acute dermal toxicity with CAS 11 -42 -2. Rabbits were exposed to the substance for 24 h under occlusive dressing. Value was given as 11.89 mL/kg and LD50 was calculated to be 13000 mg/kg bw with the specific density of 1.1 g/cm^3 published for this substance. No further data was given.
Justification for classification or non-classification
Classification,
Labelling, and Packaging Regulation (EC) No 1272/2008
The
available experimental test data of three source substances are reliable
and suitable for classification purposes under Regulation (EC) No
1272/2008, applying a read-across approach. The oral LD50 was determined
to be 1080 mg/kg bw and 1100 mg/kg bw for source substance 2 and 3,
respectively. Therefore, and equivalent to both source substances, the
test item is classified for acute oral toxicity cat 4 (H302: "harmful if
swallowed") under Regulation (EC) No 1272/2008, as amended for the tenth
time in Regulation (EU) No 2017/776.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
